AGEs	Advanced glycation end-products
ADA	American Diabetes Association
Ang-II	Angiotensin –II
ACE-i	Angiotensin-converting enzyme inhibitors
ARBs	Angiotensin Receptor Blockers
ADMA	Asymmetric dimethylarginine
BNP	Brain-Natriuretic-Peptide
CV	Cardiovascular
CKD	Chronic Kidney Disease
DM	Diabetes Mellitus
DN	Diabetic nephropathy
DKD	Diabetic kidney disease
ESKD	End-stage-kidney-disease
ERA	Endothelin-1 receptor antagonists
ETAr	Endothelin-1 binding to ET receptors type A
eGFR	Estimated glomerular filtration rate
ECM	Extracellular matrix
KDIGO	Global Outcomes Work Group
GLP1-RA	Glucagon-like peptide-1 receptor agonists
GDF-15	Growth differentiation factor-15
hs-cTnT and hs-cTnI	High-sensitivity cardiac troponins
IGF-1	Insulin-like growth factor 1
JAK-STAT	Janus kinase/signal transducers and activators of transcription
KIM-1	Kidney Injury Molecule -1
mTORC1	Mammalian target of rapamycin complex 1
MACE	Major cardiovascular events
MMP-10	Matrix metalloproteinases—10
MRA	Mineralocorticoid receptor antagonist
NGAL	Neutrophil Gelatinase-Associated Lipocalin
NO	Nitric oxide
NP-DN	Non-proteinuric diabetic nephropathy
NF-κB	Nuclear factor-κB
PKC	Protein kinase C
uPAR	Protein urokinase receptor
ROS	Reactive oxygen species
RAASi	Renin-angiotensin-system inhibitors
RBP-4	Retinol-binding protein-4
SGLT2is	Sodium-glucose co-transporter inhibitors
suPAR	Soluble urokinase-type plasminogen activator receptor
SDMA	Symmetric Dimethylarginine
T1DM	Type 1 diabetes mellitus
T2DM	Type 2 diabetes mellitus
TGF-β1	Transforming growth factor—β1
TNFR-1 and TNFR-2	Tumor Necrosis Factors receptors
ULK1	Unc-51-like kinase 1
VEGF	Vascular endothelial growth factor